Cargando…

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease

IMPORTANCE: The most important surrogate for increased risk of adverse clinical outcomes among patients with nonalcoholic fatty liver disease (NAFLD) is the patient’s stage of liver fibrosis. There is a significant barrier to risk-stratifying patients in clinical practice owing to the need for liver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Younossi, Zobair M., Felix, Sean, Jeffers, Thomas, Younossi, Elena, Nader, Fatema, Pham, Huong, Afendy, Arian, Cable, Rebecca, Racila, Andrei, Younoszai, Zahra, Lam, Brian P., Golabi, Pegah, Henry, Linda, Stepanova, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446814/ https://www.ncbi.nlm.nih.gov/pubmed/34529067 http://dx.doi.org/10.1001/jamanetworkopen.2021.23923

Ejemplares similares

Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices
por: Younossi, Zobair M., et al.
Publicado: (2021)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
por: Alqahtani, Saleh A., et al.
Publicado: (2021)

Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor
por: Stepanova, Maria, et al.
Publicado: (2016)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
por: Arshad, Tamoore, et al.
Publicado: (2018)

Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
por: Paik, James M., et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
por: Paik, James M., et al.
Publicado: (2020)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
por: Paik, James M, et al.
Publicado: (2020)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
por: Golabi, Pegah, et al.
Publicado: (2019)

Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC
por: Younossi, Zobair M., et al.
Publicado: (2023)

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
por: Younossi, Zobair M., et al.
Publicado: (2021)

Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example
por: Page, Sandra, et al.
Publicado: (2013)

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
por: Weinstein, Ali A, et al.
Publicado: (2022)

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C)
por: Birerdinc, Aybike, et al.
Publicado: (2012)

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
por: Golabi, Pegah, et al.
Publicado: (2016)

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2017)

Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection
por: Price, Jillian Kallman, et al.
Publicado: (2023)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Exercise as an intervention for patients with end-stage liver disease: Systematic review
por: Locklear, Cameron T., et al.
Publicado: (2018)

The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry
por: Younossi, Zobair M., et al.
Publicado: (2022)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007‐2017
por: Paik, James M., et al.
Publicado: (2021)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin
por: Younossi, Zobair M, et al.
Publicado: (2012)

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
por: Golabi, Pegah, et al.
Publicado: (2019)

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
por: Golabi, Pegah, et al.
Publicado: (2020)

Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease
por: Younossi, Zobair, et al.
Publicado: (2022)

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease
por: Younossi, Zobair M., et al.
Publicado: (2018)

Sarcopenia, healthy living, and mortality in patients with chronic liver diseases
por: Van Dongen, Catherine, et al.
Publicado: (2022)

The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
por: Paik, James M., et al.
Publicado: (2023)

The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19
por: Stepanova, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vl3gv6mlbbeck4t4btppk0k1sj